Skip to main content
Clinical Trials/JPRN-UMIN000017138
JPRN-UMIN000017138
Completed
未知

Phase II trial of dose dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer - KCOG-G-1301 trial

Kansai Clinical Oncology Group0 sites48 target enrollmentApril 20, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Advanced or recurrent uterine corpus cancer
Sponsor
Kansai Clinical Oncology Group
Enrollment
48
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 20, 2015
End Date
March 17, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kansai Clinical Oncology Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)motor or sensory neuropathy with dysfunction 2\) alcoholic hypersensitivity 3\)bacterial infection to needtreatment 4\) myocardial infarction within 6 months 5\) unstable angina 6\) poor control diabetes 7\) active multiple malignancy 8\) Interstitial pneumonia, pulmonary fibrosis 9\) Paclitaxel or CBDCA is contra\-indicated. 10\) HBs\-Ag(\+) 11\) Paralytic or mechanical bowel obstruction 12\) History of severe drug\-induced hypersensitivity syndrome 13\) Any other cases who are regarded as inadequate for study enrollment by investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials